Patients’ and Healthcare Professionals’ Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational Survey Lisa H. Lancaster Claudia Valenzuela Wendi Mason Claus Neurohr Elena Ripamonti Klaus-Uwe Kirchgaessler Vincent Cottin 10.6084/m9.figshare.11871381.v1 https://adisjournals.figshare.com/articles/figure/Patients_and_Healthcare_Professionals_Experiences_of_Idiopathic_Pulmonary_Fibrosis_Treatment_with_the_Pirfenidone_801_mg_Tablet_Formulation_A_Multinational_Survey/11871381 <p>The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).<br></p> <p>© The authors, CC-BY-NC 2020. </p><p></p> 2020-03-10 11:13:28 Antifibrotics Idiopathic pulmonary fibrosis Pill burden Pirfenidone Quality of life Questionnaire